home
about
platform
science
news
contact
中
/
EN
news
2026-03-25
Superior Efficacy and Long-acting: LongBio Announces Positive Topline Results from Phase II CSU Trial of Next-Generation Anti-IgE Therapy, LP-003 in Head-to-Head Comparison with Omalizumab
more
2025-03-03
Breakthrough! Exciting interim Phase II Data of LP-003 in CSU released by Longbio at AAAAI 2025
more
2024-11-25
Food Allergy: LongBio's LP-003 achieves its fourth IND approval
more
2024-09-24
LongBio announced the completion of Series B2 financing, led by Qiming Venture Partners
more
2024-04-16
Pre-clinical result of LP-005, a novel bi-functional complement antibody-fusion protein was unveiled by LongBio at WCN2024
more
1
2
